Cancer Immunology and Immunotherapy: From Defining Basic Immunology to Leading the Fight Against Cancer

References

• Abdollahi A, Folkman J. 2010. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 13(1–2):16–28.
   PubMed Web of Science ®Google Scholar
• Adler AJ. 2007. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets. 7(1):3–14.
   PubMed Web of Science ®Google Scholar
• Adler AJ, Vella AT. 2013. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology. 2(1):e22837.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. 2007. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 13(9):1050–59.
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. 2016. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 34539-73(1):539–73.
   Google Scholar
• Brennick CA, George MM, Corwin WL, Srivastava PK, Ebrahimi-Nik H. 2017. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. Immunotherapy. 9(4):361–71.
   PubMed Web of Science ®Google Scholar
• Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, et al. 2021. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 596(7870):126–32. doi:10.1038/s41586-021-03752-4.
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Guevara-Patino JA. 2022. Barriers and opportunities for CAR T-cell targeting of solid tumors. Immunol Invest. 1–11. doi:10.1080/08820139.2022.2096463
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al. 2006. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 355(23):2408–17.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. 2010. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 363(9):809–19.
   PubMed Web of Science ®Google Scholar
• Fu C, Ma T, Zhou L, Mi QS, Jiang A. 2022. Dendritic cell-based vaccines against cancer: challenges, advances and future opportunities. Immunol Invest. 1–26. doi:10.1080/08820139.2022.2109486
   Web of Science ®Google Scholar
• Ghoneim HE, Fan Y, Moustaki A, Abdelsamed HA, Dash P, Dogra P, Carter R, Awad W, Neale G, Thomas PG, et al. 2017. De Novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell. 170(1):142–57 e19.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363(5):411–22.
   PubMed Web of Science ®Google Scholar
• Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al. 2013. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 123(3):1371–81.
   PubMed Web of Science ®Google Scholar
• Koguchi Y, Redmond WL. 2022. A novel class of on-treatment cancer immunotherapy biomarker: trough levels of antibody therapeutics in peripheral blood. Immunol Invest. 1–17. doi:10.1080/08820139.2022.2131570
   PubMed Web of Science ®Google Scholar
• Lim WA, June CH. 2017. The principles of engineering immune cells to treat cancer. Cell. 168(4):724–40.
   PubMed Web of Science ®Google Scholar
• Long M, Mims AS, Li Z. 2022. Factors affecting the cancer immunotherapeutic efficacy of T cell bispecific antibodies and strategies for improvement. Immunol Invest. 1–39. doi:10.1080/08820139.2022.2131569
   PubMed Web of Science ®Google Scholar
• Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T. 1989. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell. 58(2):293–303.
   PubMed Web of Science ®Google Scholar
• Mellman I, Turley SJ, Steinman RM. 1998. Antigen processing for amateurs and professionals. Trends Cell Biol. 8(6):231–37.
   PubMed Web of Science ®Google Scholar
• Mihalyo MA, Hagymasi AT, Slaiby AM, Nevius EE, Adler AJ. 2007. Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate. 67(5):67536–46.
   Web of Science ®Google Scholar
• Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, et al. 2019. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 20(3):326–36.
   PubMed Web of Science ®Google Scholar
• Milstein C. 1999. The hybridoma revolution: an offshoot of basic research. Bioessays. 21(11):966–73.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, Banchereau J. 2007. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 220(1):220129–50.
   Google Scholar
• Ryder LP, Svejgaard A, Dausset J. 1981. Genetics of HLA disease association. Annu Rev Genet. 15(1):15169–87.
   Google Scholar
• Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, et al. 2012. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med. 209(3):495–506.
   PubMed Web of Science ®Google Scholar
• Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, et al. 2019. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 25(1):89–94.
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Lim M, DeWeese TL, Drake CG. 2015. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16(13):e498–509.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science. 348(6230):56–61.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al. 2018. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 557(7706):575–79.
   PubMed Web of Science ®Google Scholar
• Snell GD. 1981. Studies in histocompatibility. Science. 213(4504):172–78.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, et al. 2022. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 386(1):24–34.
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Rosenberg SA. 2017. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 18(3):255–62.
   PubMed Web of Science ®Google Scholar
• Ward Grados DF, Ahmadi H, Griffith TS, Warlick CA. 2022. Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Invest. 1–26. doi:10.1080/08820139.2022.2118606
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. 2015. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 15(8):486–99.
   PubMed Web of Science ®Google Scholar
• Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, et al. 2019. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 25(8):1251–59.
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Doherty PC. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 248(5450):701–02.
   PubMed Web of Science ®Google Scholar